2型糖尿病患者血清高敏C反应蛋白与尿蛋白及血清总抗氧化能力的相关性研究

目的:探讨2型糖尿病(T2DM)肾病、糖耐量受损(IGT)者及正常对照组血清中高敏C反应蛋白(Hs-CRP)与尿蛋白(U-Pro)及血清总抗氧化能力(TAOC)的关系。方法:选取76例T2DM肾病患者、65例IGT患者与60例对照者(NGT),分别测定其血清Hs-CRP、U-Pro、TAOC等指标。结果:T2DM肾病组和IGT组血清Hs-CRP明显高于NGT组(P<0.01),IGT组血清总抗氧化能力水平明显低于NGT组;相关性分析显示血清Hs-CRP水平与U-Pro呈显著正相关(r=0.191,P<0.05),但U-Pro水平与血清TAOC相关性不显著。结论:T2DM及IGT患者血清Hs-CRP及TAOC与肾损伤具有明显的相关性,Hs-CRP水平升高及TAOC水平降低是血糖异常者肾损伤的可能原因之一,可作为2型糖尿病肾病发生、发展和预后的判断指标之一,对准确评估T2DM及IGT患者肾损伤危险度有一定价值。     

柴胡疏肝散治疗非酒精性脂肪肝的系统评价与Meta分析

目的评价柴胡疏肝散治疗非酒精性脂肪肝(NAFLD)的有效性与安全性。方法计算机检索10个中英文数据库(时间均自建库至2013年12月),纳入柴胡疏肝散治疗NAFLD随机对照试验(RCT)的文献,对其方法学质量及终点指标行定性与定量合成分析。结果共纳入10个RCT合计802例NAFLD受试者,其方法学质量均属于高偏倚风险。所有RCT试验组采用柴疏肝散加减或结合西药治疗,对照组采用西药治疗,均未报告主要终点,而仅报告次要终点,只有2个RCT报告不良反应结局。对次要终点行Meta分析结果显示,试验组治疗后总胆固醇、低密度脂蛋白、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶及总有效率均优于对照组。结论柴胡疏肝散治疗NAFLD有效且安全,但由于所纳入RCT方法学质量均较低,需要开展更为严格的RCT以提供充分证据支持临床应用柴胡疏肝散治疗NAFLD。     

辛开苦降法合“标准三联”治疗幽门螺杆菌阳性慢性非萎缩性胃炎临床研究

目的研究辛开苦降法合西药"标准三联"治疗幽门螺杆菌(Helicobacter pylori,Hp)阳性的慢性非萎缩性胃炎的临床疗效。方法将84例Hp阳性的慢性非萎缩性胃炎患者随机分为两组,治疗组42例应用加味半夏泻心汤合抗Hp的西药"标准三联"治疗;对照组42例单纯应用"标准三联"治疗。两组均分别治疗14 d,停药30 d后,复查Hp并判断治疗前后临床症状积分的改变情况。结果对照组治疗后Hp根除率为76.2%,治疗组为92.2%,两组比较差异有统计学意义(P0.05)。对于整体积分疗效中,对照组总有效率为81.0%,治疗组为95.2%,两组比较差异有统计学意义(P0.05)。结论辛开苦降法合"标准三联"治疗Hp阳性的慢性非萎缩性胃炎,比单纯应用西药,可更好的根除Hp和改善临床症状。     

功能性踝关节不稳足底压力分析

目的 观察功能性踝关节不稳(FAI)患者的足底压力分布特征。     

心房颤动伴短联律间期宽QRS波散点图的类型及特征

目的观察心房颤动(简称房颤)及房颤伴不同起源宽QRS波的心电散点图图形特征。方法对77例房颤及房颤伴短联律间期宽QRS波的病例进行动态心电图诊断,并制作每份病例24 h心电散点图。按照动态心电图诊断,将纳入病例分为房颤组、房颤伴室性早搏组(简称室早组)、房颤伴差异性传导组(简称差传组)、房颤伴预激组(简称预激组),观察各组图形特征。结果房颤组42例、室早组20例、差传组14例、预激组1例。全部病例均呈现有扇形散点图图形,各组又都存在特异性的图形,室早组有房室分离的图形特征,差传组有联律间期"趋短的"图形特征,预激具有经旁道连续房室传导的图形特征。结论在动态心电图中,不同原因导致的频发短联律间期宽QRS波具有不同的心电散点图特征。     

胃病1号方治疗脾胃虚寒性功能性消化不良：一项多中心、双盲、安慰剂对照试验

Objective

To assess the efficacy and safety of Gastrosis No.1 compound in the treatment of functional dyspepsia with Spleen (Pi) and Stomach (Wei) deficiency-cold syndrome.

Methods

A randomized, double-blind, placebo-controlled trial was performed in 5 centers. Patients with functional dyspepsia (FD) of Spleen-deficiency and qi-stagnation syndrome (162 cases) were randomly assigned to groups given Chinese herbal medicine (CHM) Gastrosis No.1 compound or placebo in a 2:1 ratio. This trial included a 4-week treatment period and a 4-week follow-up period. The outcomes were the dyspepsia symptom scores (measured by total dyspepsia symptom scale and single dyspepsia symptom scale) and syndromes of traditional Chinese medicine score (measured by traditional Chinese medicine syndrome scale). The outcomes were noted at weeks 0, 4 and 8.

Results

Compared with patients in the placebo group, patients in the CHM group showed significant improvement in the dyspepsia symptom scores as rated by patients and investigators (P <0.01), and also showed improvement in syndromes of traditional Chinese medicine score (P <0.01). No serious adverse event was reported. Safety tests obtained after 4 weeks of treatment showed no abnormal values.

Conclusion

CHM Gastrosis No.1 compound was effective and safe in the treatment of functional dyspepsia with Spleen and Stomach deficiency-cold syndrome     

经皮耳迷走神经刺激干预功能性消化不良模型大鼠的效应及机制研究

ObjectiveTo explore the effect and its possible mechanism of the intervention of transcutaneous auricular vagus nerve stimulation (taVNS) for the functional dyspepsia (FD) model rats.MethodsOf the 25 male SD rats, 6 rats were set as blank group, the other 19 rats were established to be the functional dyspepsia (FD) model by iodoacetamide intragastric administration, and 18 FD models were successfully established. The 18 model rats were randomly divided into a model group, a sham-taVNS group, and taVNS group, with 6 rats in each group. There was no intervention applied to the rats in the blank and model groups. Whereas, the rats in sham-taVNS group received stimulation to the rim of auricular concha of both sides, and those in taVNS group received stimulation to the cavity of auricular concha of both sides, for 30 min each time, once a day, 7 days in succession. After the intervention, the gastric sensitivity of the rats in each group under different pressure conditions in the stomach, the expressions of serum brain-gut peptide motilin (MTL), cholecystokinin (CCK), glucagon-likepeptide1 (GLP-1), and inflammatory factors IL-4, IL-10, and IL-1β were detected.Results(1) Gastric sensitivity: compared with the blank group, the gastric sensitivity of the model group was higher (P <0.05). Compared with the model group, the gastric sensitivity of the taVNS group was lower (P < 0.05). Compared with the sham-taVNS group, the gastric sensitivity of the taVNS group was lower (P <0.05).(2) Expression of brain-gut peptide: compared with the blank group, MTL was lower, CCK and GLP-1 were higher in the model group (all P <0.05). Compared with the model group, MTL was higher, CCK and GLP-1 were lower in the taVNS group (all P <0.05). Compared with the sham-taVNS group, CCK and GLP-1 were lower in the taVNS group (both P<0.05). (3)Expression of inflammatory factors: compared with the blank group, IL-4 and IL-10 were lower and IL-1β was higher in the model group (all P <0.05). Compared with the model group, IL-10 was higher and IL-1β was lower in the sham-taVNS group (all P <0.05), while IL-4 and IL-10 were higher and IL-1β was lower in the taVNS group (all P <0.05). Compared with the sham-taVNS group, IL-4 and IL-10 were higher and IL-1β was lower in the taVNS group (all P <0.05).ConclusionTaVNS can reduce the gastric sensitivity of FD model rats by peripheral anti-inflammatory action and regulating the abnormal secretion of brain-gut peptide.     

三棱火针加拔罐治疗腘窝囊肿30例

ObjectiveTo explore the therapeutic effect of the fire needling with the three-edged needle and the cupping on popliteal cyst.MethodsA total of 60 patients of popliteal cyst were divided into two groups, 30 cases in each one according to the random number table. In the fire needling group, the burnt-red three-edged needle was inserted to the deep layer of the cyst. After the fluid was squeezed out, the cupping was exerted. The treatment was given 1 to 2 times a week, for 4 weeks totally. In the western medication group, prednisolone acetate 25 mg was injected in the cyst capsule, once a week, for 4 weeks totally. The effective rate, recurrence rate and Rauschning–Lindgren grading were evaluated before and after treatment.ResultsThe total effective rate was 80.0% in the fire needling group and was 83.3% in the western medication group, without statistical significance in comparison (P > 0.05). The recurrence rate was 6.7% in the fire needling group and was 30% in the western medication group. The recurrence rate in the fire needling group was lower than that in the western medication group, indicating the statistical significance (P < 0.05). After treatment, Rauschning–Lindgren grade was different statistically as compared with that before treatment in either group (both P < 0.05). Rauschning–Lindgren grade was distributed in 0 to I in the fire needling group after treatment, which was different significantly as compared with the western medication group (P < 0.05).ConclusionThe combined treatment with the fire needling combined with cupping therapy achieves the satisfactory effect on popliteal cyst and the very low recurrence rate and it is easy in operation and deserves to be promoted in primary care.     

The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials

PurposeChemotherapy-induced hepatorenal toxicity often decreases tolerance for further therapies and results in poor quality of life and prognosis for patients with lung cancer. In this meta-analysis, all related studies were systematically re-evaluated to determine whether Aidi injection relieves hepatorenal toxicity and improves tumor response, and to determine its threshold and the optimal treatment regimen for obtaining the desired responses.MethodsAll studies regarding Aidi injection with chemotherapy were gathered from Chinese and English databases (from inception until January 2019). Their bias risk was evaluated and the data were synthesized using meta-analysis; the quality of evidence of all outcomes was rated by using the Grades of Recommendation Assessment, Development, and Evaluation approach.FindingsEighty randomized controlled trials containing 6279 patients were included in the study. Most of the trials showed unclear risk of bias. Aidi injection with chemotherapy increased the objective response rate (risk ratio [RR], 1.32; 95% CI, 1.25–1.40) and the disease control rate (RR, 1.15; 95% CI, 1.12–1.17) and resulted in a lower incidence of hepatotoxicity (RR, 0.61; 95% CI, 0.55–0.69) and nephrotoxicity (RR, 0.62; 95% CI, 0.53–0.72) than that of chemotherapy alone. Subgroup analyses showed that treatment with 50 mL per time, 10 to 14 days per cycle, and 2 to 3 cycles of Aidi injection with chemotherapy resulted in a low incidence of hepatorenal toxicity. All of the results were robust, and their quality was moderate.ImplicationsThe moderate evidence indicates that Aidi injection with chemotherapy may improve tumor response and result in a low incidence of hepatorenal toxicity in patients with lung cancer. Aidi injection may relieve hepatorenal toxicity and exhibit an important protective effect against chemotherapy-induced hepatorenal toxicity. Based on the subgroup analysis results, Aidi injection seems to lower the threshold for chemotherapy. Treatment with 50 mL per time, 10 to 14 days per cycle, and 2 to 3 cycles may be the optimal usage for attaining a decrease in hepatorenal toxicity.     

骨碎补总黄酮治疗绝经后骨质疏松症的Meta分析

目的系统评价骨碎补总黄酮(强骨胶囊)治疗绝经后骨质疏松症(PMOP)的疗效及安全性。方法计算机检索CNKI、CBM、VIP、万方数据库、PubMed、Embase、Cochrane图书馆,检索时间是自建库以来至2017年11月3日,按照纳排标准,收集强骨胶囊治疗PMOP的临床对照试验,依据Cochrane Handbook for Systematic Reviews of Interventions(version 5.35)质量评估,并使用RevMan5.3软件进行Meta分析。结果纳入6篇文献,8个研究。在有效率[RR=1.50,95%CI(1.04～2.17),P=0.03]和提高股骨骨密度[MD=0.04,95%CI(0.02～0.06),P=0.0002]方面,强骨胶囊联合常规治疗可能优于单独常规治疗;在提高腰椎骨密度[MD=0.02,95%CI(-0.01～0.05),P=0.28]、髋骨骨密度[MD=-0.05,95%CI(-0.09～0.00),P=0.05]、改善血钙[MD=0.01,95%CI(-0.06～0.08),P=0.77]、血磷[MD=0.02,95%CI(-0.05～0.09),P=0.58]、血碱性磷酸酶[MD=4.28,95%CI(-6.98～15.54),P=0.46]等指标方面,与常规治疗组相比,差异无统计学意义。强骨胶囊的不良反应包括便秘、口干、恶心、胃肠道反应,经对症处理后缓解,不需停药。结论强骨胶囊在改善患者症状及股骨骨密度方面,可能有一定的辅助治疗作用。而在改善血钙、血磷、血碱性磷酸酶、血骨钙素等客观指标方面,可能无明显优势,但具有较好的安全性。